louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00883961: Exercise Following Autologous Peripheral Blood Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Hematological Disease
Keywords: High-dose chemotherapy
Hematological neoplasties
Fatigue
Cancer
Exercise
Sport
Hematologic neoplastic disorders
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2009-04-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study evaluates the effects of a supervised exercise program on the physical performance, the mood and the complications of therapy in patients undergoing a high-dose chemotherapy followed by an autologous peripheral blood stem cell transplantation.


Eligibility criteria: Inclusion Criteria:

* Age 18-70
* Hematological disease
* Treatment with high-dose chemotherapy followed by autologous stem cell transplantation
* Understanding of written German

Exclusion Criteria:

* Cardiorespiratory, metabolical, osteoarticular or immunological diseases which can be aggravated by exercise
* Pathological stress-ECG at admission

Primary outcomes:
measure: VO2max
timeFrame: At recruitment and after 3 weeks
Secondary outcomes:
measure: Mood
timeFrame: At recruitment and after 3 weeks
measure: Duration of aplasia
timeFrame: 3 weeks
measure: Complications during hospitalization
timeFrame: 3 weeks
measure: Need for transfusion of platelets and red blood cells
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30
Study officials:
affiliation: Charite University, Berlin, Germany
name: Fernando Dimeo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02732561: The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults
Official title: The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Anxiety
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2016-04-08
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a trial of the use of cranial electrostimulating therapy for depression and anxiety among homeless adults.

Detailed description: Cranial Electrostimulating (CES) Therapy is a Food and Drug Administration (FDA) approved treatment for depression and anxiety. However, there are no known studies on the use of this device with homeless adults. The objectives of this study are as follows: 1) to evaluate the acceptability and feasibility of CES as a treatment for homeless adults; and 2) to evaluate the efficacy of CES for the treatment of anxiety and depressive symptoms among homeless adults. Participants will be randomly assigned to one of two treatments: sham (n=10) or CES (n=10). Changes in anxiety and depressive symptoms will be evaluated over time.

Eligibility criteria: Inclusion Criteria:

* Competent (no legal guardian) males and females between the ages of 18 to 64
* Currently homeless or recent experience of homelessness, and symptoms of anxiety or depression

Exclusion Criteria:

* Younger than 18 and older than 65
* Patients who have attempted suicide with within the past twelve months or have active suicidal ideation will be excluded for possible safety concerns
* Self-reported illegal substance use in the past 30 days. Recent use of nicotine and alcohol will be allowed. However, those with current intoxication will be excluded
* History of a seizure disorder.
* Current history of autoimmune or endocrine disorder affecting the brain, unstable cardiac disease, history of skull fracture, or craniotomy
* Patients with pacemakers or internal electronic devices like deep brain stimulation and cochlear implants
* Women who are pregnant, nursing or planning to become pregnant
* Diagnosis of Schizophrenia or Schizoaffective disorder

Primary outcomes:
measure: Depressive Symptoms
timeFrame: 4 weeks
measure: Anxiety
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
Study officials:
affiliation: Wake Forest Health Sciences
name: James Kimball, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01240161: Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Official title: Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: High Grade Glioma
Keywords: Glioblastoma multiforme
FLT
PET
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: Society of Nuclear Medicine and Molecular Imaging
name: General Electric
First posted: 2010-11-15
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting to BWH/DFCI emergency department (ED), inpatient, or neurology/ neurosurgery/ radiation oncology clinics with newly diagnosed brain masses (suspected high grade gliomas) will be consented and enrolled in this study after adequate explanation of the risks and benefits of the study.

Brief summary: The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
* Anticipated survival ≥6 months
* Able to give informed consent
* Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
* Male or Female

Exclusion Criteria:

* Prior radiation therapy and chemotherapy to the brain
* Active intracranial infection or nonglial brain mass.
* Recent large intracranial hemorrhage (\<1 month)
* Expected survival \<6 months
* Pregnant or nursing
* Renal failure
* Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.

Primary outcomes:
measure: Overall Survival
timeFrame: 7 months
measure: Progression free Survival
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: University of California at San Diego
state: California
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Marie Kijewski, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03383861: Nutrition Status, BMD, and SSRIs
Official title: Nutrition Status, Bone Mass Density, and Selective Serotonin Reuptake Inhibitors
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: BMD
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2017-12-26
Enrollment: 13027
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: NHANES participants

Brief summary: The association between selective serotonin reuptake inhibitor (SSRI) use and bone mass density (BMD) has been debated. Some have suggested features of depression, which SSRIs are prescribed to treat, may be a cause of decreased BMD, such as poor overall food intake at the time of SSRI use. Our study seeks to determine whether SSRI use in adults is associated with lower than average BMD, and if there is an association between low micronutrient intake, SSRI use, and a low BMD.


Eligibility criteria: Inclusion Criteria:

* Included adult NHANES participants are those who participated in the Dual-Energy X-ray Absorptiometry (DXA) femur-neck BMD test and responded in full to the demographic, pharmaceutical, and dietary surveys.

Exclusion Criteria:

* Pregnancy, incomplete survey responses, incomplete DXA results

Primary outcomes:
measure: BMD t-score
timeFrame: NHANES DXA measurement taken 2005-2014
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06962761: the Effect of Use of Vit d and Probiotic as a Supplementaition in the Treatment of Bronchial Asthma in Patient Aged 6 to 50 Year and Its Effect in Decrasing Excerbation.
Official title: Impact of Vit D and Probiotic As a Supplementary Therapy in The Treatment of PatientWith Bronchial Asthma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bronchial Asthma
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2025-05-08
Enrollment: 200
Sex: ALL
Minimum age (years): 6
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patient wih bronchial asthma

Brief summary: the study of the effect of vit d and probiotic as suprplementaion in the treatment of patient with bonchial asthma and its effect in decreasing number of excerbation

Detailed description: the study of the effect of vit d and probiotic as suprplementaion in the treatment of patient with bonchial asthma and its effect in decreasing number of excerbation

Eligibility criteria: Inclusion Criteria: patient wih bronchial asthma aged 6 to50years -

Exclusion Criteria: other comorbities

-

Primary outcomes:
measure: asthma control test
timeFrame: 3,6 and 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: ALAzhar university hospital assiut
Study officials:
References:
Clinical trial NCT06256783: A Clinical Study of Baozhu Keli in the Treatment of Ovarian Aging
Official title: The Efficacy and Safety of Chinese Herbal Compound Baozhu Keli in the Treatment of Ovarian Aging: A Multicenter and Prospective Study.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Ovarian Aging
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-02-13
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Ovarian aging (OA) seriously affects the physical and mental health of women. Nowadays, Chinese herbs have huge appeal and potential in treating OA. We have created a new Chinese herbal combination Baozhu Keli, whereas its safety and efficacy still need to be validated. Hence, we will perform a population-based, multicenter study to confirm the safety and efficacy of Baozhu Keli in therapy of OA. We aim to provide a solid evidence for TCM in therapy of OA.


Eligibility criteria: Inclusion Criteria:

1. The age range of patient is 18-40 years old.
2. The diagnostic criteria for ovarian aging.
3. Sign the informed consent form.

Exclusion Criteria:

1. Patient is known to be allergic or unsuitable for the Chinese herbal compound.
2. Women who are pregnant and lactating.
3. Abnormal uterine bleeding, except ovulation disorders.
4. Women is taking hormone drugs and has stopped taking them within 3 months;
5. Women with endometriosis, myadenosis, submucosal fibroids or the size of non- submucosal fibroids is more than 4 cm.
6. The nature of pelvic mass is unknown.
7. Women with polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, diabetes, thyroid and adrenal dysfunction and other endocrine diseases affecting ovulation.
8. Patients with serious primary diseases such as cardiovascular, liver, kidney, lung, biliary, hematopoietic system (Hb\<90g/L) and malignant tumor, and psychiatric patients.
9. Patients are participating in other clinical trials or have participated in other clinical trials within the last month.
10. Unsuitable for the study evaluated by the investigator.

Primary outcomes:
measure: the recovery rate of ovarian function
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study officials:
affiliation: Tongji Hospital
name: Jinjin Zhang, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT02138461: Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
Official title: Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Keywords: glaucoma
bimatoprost
latanoprost
tolerability
Lead sponsor: MDbackline, LLC
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2014-05-14
Enrollment: 211
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients taking either study medication for glaucoma.

Brief summary: This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.

Detailed description: Patients enrolled in this study completed a validated survey instrument (COMTOL) examining tolerability of topically applied ophthalmic medications that they are already taking in their regular course of care for glaucoma. The purpose of the study is to determine whether side effects and symptoms of the drugs already being taken cause problems with activities of daily living.

Eligibility criteria: Inclusion Criteria:

* Patients with glaucoma taking either bimatoprost or latanoprost

Exclusion Criteria:

* patients taking other medication or with other causes for ocular surface symptoms

Primary outcomes:
measure: Tolerability of Medications as Measured by the COMTOL Validated Instrument
timeFrame: at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study
Secondary outcomes:
Other outcomes:
Locations:
city: Laguna Hills
country: United States
facility: Harvard Eye Associates
state: California
Study officials:
affiliation: UCLA Jules Stein Eye Institute
name: John A. Hovanesian, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Harvard Eye Associates
name: Savak Teymoorian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01094483: A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
Official title: A Phase I Prospective, Randomized, Double-blind, Placebo-controlled Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN 400 and Low Dose Aspirin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Platelet Inhibition
Keywords: Thromboxane B2
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: POZEN
First posted: 2010-03-29
Enrollment: 40
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane B2 inhibition.


Eligibility criteria: Inclusion Criteria:

* Stable without clinically significant disease

Exclusion Criteria:

* Use of NSAID within 2 weeks
* Type 1 or 2 DM
* GI disorder

Primary outcomes:
measure: Pharmacodynamic: Mean percent inhibition of serum thromboxane B2
timeFrame: measured on the morning of Day 6 (Period 1), and 24 hours after the Day 10 morning dose of aspirin (ie, Day 11) in Period 2
measure: Safety: Parameters include: physical examination, vital signs, clinical laboratory tests, adverse events
timeFrame: during approx 6 week study period
Secondary outcomes:
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Research Site
state: Kansas
Study officials:
affiliation: Quintiles Phase 1 Services
name: Ralph Schutz, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca
name: Catherine Datto, MD
role: STUDY_DIRECTOR
References:
citation: Angiolillo DJ, Hwang C, Datto C, Desai B, Sostek M. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. Clin Ther. 2011 Dec;33(12):1883-93. doi: 10.1016/j.clinthera.2011.10.009. Epub 2011 Nov 10.
Clinical trial NCT00452283: Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
Official title: The Effect of a Systemic Non-selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Pulmonary Hypertension
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2007-03-27
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with pulmonary hypertension

Brief summary: There is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a disease characterized by low oxygen levels in the blood and altered blood circulation. The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(NFL)in the retina and the resulting visual field compromise. This situation is characteristic of glaucoma. The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss.

We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.


Eligibility criteria: Inclusion Criteria:

* diagnosed with pulmonary hypertension
* between the ages of 18 and 80 years
* ability to undergo the various ocular exams.

Exclusion Criteria:

* patients with other diseases that could affect the nerve fiber layer
* special populations; ie children, pregnancy, lactating females, prisoners

Primary outcomes:
measure: Occurence of nerve fiber layer abnormalities
timeFrame: Single Exam
Secondary outcomes:
measure: Optic Nerve Head Structure
timeFrame: Single Exam
Other outcomes:
measure: Visual Field Defects
timeFrame: Single Exam
measure: Retinal Blood Flow Changes
timeFrame: Single Exam
Locations:
city: Aurora
country: United States
facility: University of Colorado Eye Center
state: Colorado
Study officials:
affiliation: University of Colorado School of Medicine
name: Malik Y. Kahook, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02836483: A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
Official title: A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pulmonary Tuberculosis
Lead sponsor: LigaChem Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2016-07-19
Enrollment: 79
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.

Detailed description: This study is designed to explore antituberculosis of LCB01-0371 through the assess of the early bactericidal activity, safety of administration.

Eligibility criteria: Inclusion Criteria:

1. Korean who After listening to understand the details about the clinical trial, decided to join in the clinical study, and written consent
2. The age of consent at the time of writing, only men and women under 75 years old over 19 years old
3. The First diagnosis of tuberculosis and have not received tuberculosis treatment for TB patients

Exclusion Criteria:

1. Known history of Rifampicin or Isoniazid resistance
2. Serious TB for example tuberculous encephalomeningitis, It is impossible to participate in clinical trials
3. Known History of nontuberculous mycobacteria positive
4. Other pulmonary disease which is impossible to participate in clinical trial except TB

Primary outcomes:
measure: EBA0-14
timeFrame: V2(Baseline, Day 1), V9(Day 15)
Secondary outcomes:
measure: EBA0-2
timeFrame: V2(Baseline, Day 1), V4(Day 3)
measure: EBA2-14
timeFrame: V4(Day 3), V9(Day 15)
measure: EBA2-7
timeFrame: V4(Day 3), V6(Day 8)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: T.S Sim, M.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, Kim SK, Kim SJ, Kang YS, Kim TH, Mok J, Byun MK, Park HJ, Joh JS, Park YB, Lim HS, Choi H, Lee SH, Kim H, Yang J, Kim H, Shen X, Alsultan A, Cho I, Geiter L, Shim TS. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0168421. doi: 10.1128/AAC.01684-21. Epub 2021 Dec 6.